Q-omics provides the consensus-scored DCUN1D2-AS profile across patient tissues and cancer cell-line models. DCUN1D2-AS expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DCUN1D2-AS is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, DCUN1D2-AS RNA expression shows 18,103 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where DCUN1D2-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCUN1D2-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCUN1D2-AS survival associations across molecular data types. DCUN1D2-AS RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCUN1D2-AS RNA expression–survival associations across cancer types. High DCUN1D2-AS expression shows unfavorable associations in KIRP, COAD, UVM, KICH and ACC, but favorable associations in READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for DCUN1D2-AS RNA expression.
This table summarizes DCUN1D2-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DCUN1D2-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCUN1D2-AS shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, COAD, LIHC and STAD. The BLCA box plot shows higher DCUN1D2-AS RNA expression in tumor versus normal tissue (log2 FC = +0.370, t-test p = .024).
This table shows molecular features associated with DCUN1D2-AS in patient tissues and cancer cell lines. In patient samples, DCUN1D2-AS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
